ClinicalTrials.gg

Program

HS-10380

A development code. Also written as “HS-10380 Low Dose”, “HS-10380 Medium dose” and “HS-10380 High Dose”.

Its studies are mostly in Schizophrenia, led by Hansoh Pharmaceutical Group.

Furthest: phase 3, since Aug 7, 20265 company-led studies, 3 open or runningNext primary completion: Jul 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group53 open or runningphase 3since Aug 7, 2026Jul 5, 2022Jul 31, 2028phase 3 · NCT07759869

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 5, 2022First study: phase 1 study in SchizophreniaFirst studyNCT05480592 · 76 enrolled · China
  2. Jul 10, 2023Phase 2 study in SchizophreniaNCT05964790 · 112 planned
  3. Apr 9, 2026Phase 2 study in SchizophreniaNCT07550387 · 363 enrolled · China
  4. Aug 7, 2026Phase 3 study in SchizophreniaPhase 3 reachedNCT07759869 · 500 planned · China
  5. Oct 28, 2026Phase 3 study in SchizophreniaNCT07911787 · 476 planned · China

Ahead

  1. Jul 31, 2028Primary completion: phase 3 study in SchizophreniaNCT07759869
  2. Jan 24, 2029Primary completion: phase 3 study in SchizophreniaNCT07911787

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07911787Schizophrenia · China3Not yet recruitingJan 24, 2029476
NCT07759869Schizophrenia · China3Not yet recruitingJul 31, 2028500
NCT07550387Schizophrenia · China2CompletedJan 2, 2026363
NCT05964790Schizophrenia2Not yet recruitingJun 30, 2024112
NCT05480592Schizophrenia · China1UNKNOWNJun 30, 202376

How it is read

Names in the registry

  • “HS-10380”, 4 entries
  • “HS-10380 Low Dose”, 1 entry
  • “HS-10380 Medium dose”, 1 entry
  • “HS-10380 High Dose”, 1 entry

Codes read as this program: HS10380.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.